Published in AIDS Weekly, June 11th, 2007
According to the new Pharmacor report Emerging HIV Therapies, Atripla will address the significant need for a more-convenient therapy, while the efficacy of Prezista, raltegravir, and maraviroc will benefit highly treatment- experienced patients. The report, which contains...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.